{"id":"NCT01049373","sponsor":"Pascoe Pharmazeutische Praeparate GmbH","briefTitle":"Efficacy and Safety of Lymphdiaral Basistropfen (HDC) in the Treatment of Chronic Low-back Pain","officialTitle":"Efficacy and Safety of Lymphdiaral Basistropfen (a Fixed Homoeopathic Remedy [HDC]) in the Treatment of Chronic Low-back Pain Considering Constitution and Diathesism: a Double Blind, Randomised, Placebo Controlled, Single-centre Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-12","primaryCompletion":"2007-05","completion":"2007-05","firstPosted":"2010-01-14","resultsPosted":"2012-09-06","lastUpdate":"2012-09-06"},"enrollment":221,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Low Back Pain"],"interventions":[{"type":"DRUG","name":"HDC","otherNames":["Lymphdiaral Basistropfen"]},{"type":"DRUG","name":"Placebo solution","otherNames":[]}],"arms":[{"label":"Lymphdiaral Basistropfen (HDC)","type":"EXPERIMENTAL"},{"label":"Placebo Solution","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate superiority of HDC in comparison to placebo in the treatment of chronic low-back pain in relation to pain, functional impairment, quality of life, and state of health during a 15-week treatment period.","primaryOutcome":{"measure":"Change in FFbH-R Between Screening and Week 15","timeFrame":"between screening and 15 weeks treatment","effectByArm":[{"arm":"Lymphdiaral Basistropfen (HDC)","deltaMin":8.8,"sd":15},{"arm":"Placebo Solution","deltaMin":4.1,"sd":15.3}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0426"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":21},"locations":{"siteCount":1,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":112},"commonTop":["Headache","Pruritus","Dizziness","Nasopharyngitis","Arthralgia"]}}